Eton Pharmaceuticals (ETON) Projected to Announce Quarterly Earnings on Thursday

Eton Pharmaceuticals (NASDAQ:ETON) is expected to be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Eton Pharmaceuticals to announce earnings of $0.3125 per share and revenue of $41.98 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. The firm had revenue of $37.59 million for the quarter, compared to analyst estimates of $27.11 million. On average, analysts expect Eton Pharmaceuticals to post $1.13 EPS for the current fiscal year and $1.94 EPS for the next fiscal year.

Eton Pharmaceuticals Stock Up 1.3%

NASDAQ ETON opened at $51.80 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30. The company’s 50 day simple moving average is $56.32 and its 200 day simple moving average is $35.19. Eton Pharmaceuticals has a 12 month low of $14.27 and a 12 month high of $66.37. The company has a market capitalization of $1.48 billion, a P/E ratio of 136.32 and a beta of 0.90.

Insider Activity at Eton Pharmaceuticals

In related news, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction on Friday, August 28th. The shares were sold at an average price of $59.07, for a total value of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares of the company’s stock, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Krempa sold 4,166 shares of the firm’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total value of $229,421.62. Following the transaction, the insider owned 43,381 shares in the company, valued at approximately $2,388,991.67. This trade represents a 8.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 79,166 shares of company stock valued at $4,809,672 over the last three months. Insiders own 16.49% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Craig Hallum reaffirmed a “buy” rating and set a $78.00 target price on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. B. Riley Financial restated a “buy” rating and set a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Canaccord Genuity Group boosted their price objective on Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Eton Pharmaceuticals in a report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $71.50.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.